Edition:
United Kingdom

Antares Pharma Inc (ATRS.OQ)

ATRS.OQ on NASDAQ Stock Exchange Capital Market

2.57USD
18 May 2018
Change (% chg)

$-0.03 (-0.97%)
Prev Close
$2.59
Open
$2.60
Day's High
$2.60
Day's Low
$2.57
Volume
73,919
Avg. Vol
267,342
52-wk High
$4.09
52-wk Low
$1.59

Select another date:

Tue, May 8 2018

BRIEF-Antares Pharma Reports Q1 Loss Per Share Of $0.04

* ANTARES PHARMA REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS

BRIEF-Antares Pharma Says FDA Accepts Resubmission To CRL For Xyosted NDA

* ANNOUNCED FDA ACKNOWLEDGED RECEIPT OF RESUBMISSION TO CRL RECEIVED IN CONNECTION WITH XYOSTED NEW DRUG APPLICATION

BRIEF-Antares Pharma Provides Xyosted™ Regulatory Update

* BELIEVES THAT IT DOES NOT NEED TO CONDUCT ANY NEW CLINICAL STUDIES TO SUPPORT RESUBMISSION

BRIEF-Antares Pharma Q4 Loss Per Share $0.02

* ANTARES PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS

BRIEF-Antares Pharma Provides Xyosted Regulatory Update

* ANTARES PHARMA INC - TYPE A MEETING HAS BEEN SCHEDULED WITH U.S. FOOD AND DRUG ADMINISTRATION ON FEBRUARY 21, 2018 FOR XYOSTED

BRIEF-Antares Pharma Requests Type A Meeting With FDA Regarding Xyosted

* ANTARES PHARMA - WRITTEN REQUEST FOR A TYPE A MEETING HAS BEEN SUBMITTED TO FDA IN RESPONSE TO CRL RECEIVED REGARDING NDA FOR XYOSTED Source text for Eikon: Further company coverage:

Select another date: